Uniportal thoracoscopic pulmonary lobectomy in the treatment of Lung Cancer

Treatment of Lung Cancer

  • Jinying Zhang Binzhou People’s Hospital
  • Haixia Zhao
  • Lingmei Lv
  • Jiang Yuan
  • Yuzhen Sun
Keywords: Uniportal thoracoscopy, Triportal thoracoscopy, Lung cancer


Objective: To investigate the clinical efficacy of uniportal thoracoscopic pulmonary lobectomy in the treatment of lung cancer.

Methods: One hundred and ten patients with lung cancer who were admitted to our hospital from February 2017 to June 2018 were enrolled and they were divided into the control group (55 patients) and observation group (55 patients) according to the random number table method. The patients in the observation group received uniportal thoracoscopic pulmonary lobectomy, and patients in the control group underwent triportal thoracoscopic pulmonary lobectomy. The surgical condition, postoperative pulmonary functions, postoperative complication incidence, and postoperative quality of life were compared between the two groups.

Results: The intraoperative blood loss and number of dissected lymph nodes of the observation group were (125.31±12.63) mL and (13.91±2.41) respectively, which were not significantly different with (127.54±13.60) mL and (13.96±2.69) of the control group (P>0.05). The incision length of the observation group was (4.22±0.31) cm, shorter than (6.97±0.42) cm of the control group, the postoperative pain score was (2.87±0.69) points, lower than (4.31±1.09) points of the control group, and the operation time was (195.21±19.42) minutes, longer than (162.68±18.52) min of the control group; the differences were significantly different (P<0.05). The postoperative forced vital capacity (FVC), Maximum Ventilatory Volume (MVV) and Forced Expiratory Volume in 1s (FEV1) in the observation group were (1.90±0.75) L, (54.59±16.03) L/minutes and (1.60±0.53) L respectively, larger than (1.06±0.28) L, (38.41±15.59) L/min and (1.02±0.15) L respectively (P<0.05). The scores of Short Form 36-item Health Survey (SF-36) of patients in the observation group was observed one month after surgery, significantly higher than those in the control group, and the difference was statistically significant (P<0.05). The incidence of complications of the postoperative complication of the observation group was 12.7%, which was not significantly different with 14.5% of the control group (P>0.05).

Conclusion: Patients who receive uniportal video-assisted thoracoscopic pulmonary lobectomy have milder trauma, which is beneficial to the lung functions and postoperative recovery. Moreover, the number of dissected lymph nodes in uniportal thoracoscopic pulmonary lobectomy is equivalent with that in triportal thoracoscopic pulmonary lobectomy. Hence it is worth clinical promotion.

doi: https://doi.org/10.12669/pjms.36.2.793

How to cite this:
Zhang J, Zhao H, Lv L, Yuan J, Sun Y. Uniportal thoracoscopic pulmonary lobectomy in the treatment of Lung Cancer. Pak J Med Sci. 2020;36(2):182-186. doi: https://doi.org/10.12669/pjms.36.2.793

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite
Zhang, J., Zhao, H., Lv, L., Yuan, J., & Sun, Y. (2019). Uniportal thoracoscopic pulmonary lobectomy in the treatment of Lung Cancer. Pakistan Journal of Medical Sciences, 36(2). https://doi.org/10.12669/pjms.36.2.793
Original Articles